Evidence map›Paper›PMID 35957778›Full record

ArticleClinical case reports2022

Intermittent chronic telogen effluvium with an unusual dermoscopic finding following COVID-19.

Nasrin Saki, Fatemeh Sari Aslani, Mozhdeh Sepaskhah, Mohadese Shafiei, Sara Alavizadeh, Seyed Ali Hosseini, Fatemeh Ansari Asl, Najmeh Ahramiyanpour

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. [Review of the post-COVID-19 syndrome associated to acute telogen effluvium].Revista medica del Instituto Mexicano del Seguro Social · 2023
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nasrin SakiMolecular Dermatology Research Center Shiraz University of Medical Sciences Shiraz Iran.
Fatemeh Sari AslaniMolecular Dermatology Research Center Shiraz University of Medical Sciences Shiraz Iran.
Mozhdeh SepaskhahMolecular Dermatology Research Center Shiraz University of Medical Sciences Shiraz Iran.ORCID https://orcid.org/0000-0002-8773-0019
Mohadese ShafieiDepartment of Dermatology, Afzalipour Hospital, Afzalipour Faculty of Medicine Kerman University of Medical Sciences Kerman Iran.ORCID https://orcid.org/0000-0002-5520-8752
Sara AlavizadehDepartment of Dermatology, School of Medicine Shiraz University of Medical Sciences Shiraz Iran.
Seyed Ali HosseiniPostdoctoral Researcher Shiraz University of Medical Sciences Shiraz Iran.ORCID https://orcid.org/0000-0003-4397-1539
Fatemeh Ansari AslDepartment of Dermatology, School of Medicine Shiraz University of Medical Sciences Shiraz Iran.
Najmeh AhramiyanpourDepartment of Dermatology, Afzalipour Hospital, Afzalipour Faculty of Medicine Kerman University of Medical Sciences Kerman Iran.ORCID https://orcid.org/0000-0003-3171-5933
Shiraz University of Medical Sciences · IRKerman University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various conditions, including infections, can cause telogen effluvium (TE). One of them is coronavirus disease 2019 (COVID-19), where hair loss usually begins between 2 and 12 weeks after the illness. TE can be acute or chronic, and the chronic type can be intermittent. Here, we present the case of a 17-year-old girl with severe and widespread hair loss following an upper respiratory infection suspected to be COVID-19, with the patient having a history of such attacks since childhood. Evidence from biopsy and dermoscopy indicated a diagnosis of TE.

Indexed as

COVID‐19Dermoscopytelogen effluvium

Identifiers

PMID35957778
PMCPMC9361802
OpenAlexW4291709779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.